MultiplexDX, an innovative biotechnology company is developing accurate and affordable methods of personalised cancer diagnostics. The team, which consists of experienced, renowned scientists, won the Slovak Start-up Awards 2016 and has joined the New Europe 100: “Eastern Europe's emerging technology stars” compiled by Google and the Financial Times, among others.
- Target: eliminate incorrect cancer diagnosis and save more lives thanks to the 99% accuracy of the personalised diagnostic method
- EUR 120k turnover with the existing product portfolio in a pilot phase
- Customers include the National Institute of Health, Albert Einstein College of Medicine, Düsseldorf Universitätsklinikum, Cornell University, The Rockefeller University, Vanderbilt University
- Team: renowned specialists in the field of biochemistry, biology and biophysics with experience from leading global research institutions including Rockefeller University and the National Cancer Institute, as well as pharmaceutical companies
1 000 000 €